(Reuters) - The federal health insurance program for the elderly and
disabled spends about $2 billion annually on Amgen Inc.'s
Epogen, part of a class of anti-anemia drugs called
erythropoiesis-stimulating agents .
Critics say current payment methods have promoted
aggressive treatment. Concern grew when recent studies showed
high doses could lead to heart complications or death.
Read more at Reuters.com Government Filings News
disabled spends about $2 billion annually on Amgen Inc.'s
Epogen, part of a class of anti-anemia drugs called
erythropoiesis-stimulating agents .
Critics say current payment methods have promoted
aggressive treatment. Concern grew when recent studies showed
high doses could lead to heart complications or death.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment